Skip to content

Efficacy evaluation of ketogenic diet combined with acupuncture in the treatment of obesity with polycystic ovary syndrome

Efficacy evaluation of ketogenic diet combined with acupuncture in the treatment of obesity with polycystic ovary syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116380
Enrollment
Unknown
Registered
2026-01-08
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity combined with polycystic ovary syndrome

Interventions

Ketogenic diet group:The ketogenic diet adopts a "flexible ketogenic" approach, which involves gradually reducing the proportion of carbohydrates and increasing the proportion of fat energy supply ove
Acupuncture group:The acupuncture regimen is as follows: (1) Acupoints: Zhongwan, Tianshu (both), Dahuang (both), Hua Roumen (both), Daimai (both), Zigong (both), Qihai, Guanyuan, Xuehai (both), Zusan
Ketogenic die

Sponsors

The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 and =28kg/m^2; 4. Good organ function: absolute neutrophil count >=1.5X10^9/L; platelet count >=100X10^9/L; hemoglobin >=90g/L; total bilirubin =50ml/min; 5. Patients must agree to use reliable physical contraception with their partners during and for at least 30 days after the end of the trial; 6. Patients must agree to temporarily discontinue medications that affect the menstrual cycle, such as gynecological endocrinology drugs, and medications that affect glucose metabolism, such as metformin, as well as other interventions that affect body weight during the trial; 7. Voluntary participation, understanding, and signing of the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Age 45 years; 2. Patients with high-grade epithelial neoplasia of the endometrium who require high-potency progestogen therapy; 3. Patients with impaired cardiac function or clinically significant cardiac disease; 4. Patients with congenital fat metabolism disorders; 5. Pregnant or lactating women, or those planning to become pregnant during the study period; 6. Patients with severe or uncontrolled diseases; 7. Subjects with other severe systemic diseases deemed unsuitable for participation in this study by the investigator.

Design outcomes

Primary

MeasureTime frame
Body composition;Sex hormone;Menstrual cycle;Blood sugar;Insulin;Blood lipids;Liver elastic modulus;

Secondary

MeasureTime frame
Constitution Identification;

Countries

China

Contacts

Public ContactChen Qiuxia

The Second Affiliated Hospital of Zhejiang Chinese Medical University

chenqiuxia197709@126.com+86 571 8526 7055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026